We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Fisher Biosciences and UM Collaborate to Develop Life-Sciences Technologies

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

On behalf of its Biosciences group, Fisher Scientific International Inc. has launched a five-year collaboration with the University of Michigan to develop tools for genomic and proteomic research.

The collaboration promotes opportunities for Fisher to combine its expertise with research at the Center for Chemical Genomics (CCG) within the University of Michigan's Life Sciences Institute (LSI).

Fisher will provide financial support for select research projects at the university and will have the opportunity to license new technologies resulting from that research.

The program is designed to foster the discovery of technologies in the areas of high-throughput screening and detection, protein _expression, chemical diversity and bioinformatics.

Fisher is targeting the development of procedures for protein testing and sample preparation, innovative ways of using RNA-interference products, broader applications of high-content screening and other advancements.

“These technologies will improve the efficiency and effectiveness of disease research and drug discovery and ultimately speed the development of new diagnostics and therapies,” said Leland Foster, chief executive officer of Fisher Biosciences.

“We are excited to be working with one of the world's leading research institutions. This collaboration enables our own team of world-class scientists to work in conjunction with the faculty and resources of the University of Michigan's Life Sciences Institute.”

The newly opened CCG is a key center for collaboration in the Life Sciences Institute at the University of Michigan.

It uses high-throughput chemical-screening technology and the knowledge base from drug discovery to explore broad aspects of biological space.

The targets that the CCG explores exist at every level within the organism - including biological, chemical and structural approaches - with and without particular disease targets in mind.

“This exciting program will foster innovative approaches using chemical inhibitors or activators to dissect the biological function of genes and gene products,” said David H. Sherman, Director, LSI Center for Chemical Genomics.

“The opportunity to forge close ties with Fisher Scientific and its specialty technology units promises to be highly productive and complementary.”